Citation

83 FR 52225

Canonical document for this Federal Register citation.

Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment; Draft Guidance for Industry; Availability Tuesday, October 16, 2018 83 FR 52225